Use

This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA‑cleared FISH assay. These are the most common tumor‑associated genetic changes in non‑small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR‑directed kinase inhibitors, whereas those with ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts non‑response to kinase inhibitors and poorer outcomes.